Drug profile · INN
clarithromycin
CLARITHRO 250
clarithromycin (CLARITHRO 250) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — clarithromycin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 16
- Data quality
- 0.89
Quick answer
clarithromycin (CLARITHRO 250) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
US 12115150
Biomarkers of coronavirus pneumonia
granted -
US 11090326
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 11090325
Compositions for treating ebola virus infection
granted -
US 10898439
Methods for treating helicobacter pylori infection
granted -
US 10668050
Compositions, methods and kits for treating diarrhea-predominant irritable bowel syndrome
granted -
US 10143702
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 9901638
Composition and method for treating an autoimmune disease
granted -
US 9314477
Compositions comprising rifabutin, clarithromycin, and clofazimine and uses thereof
granted -
US 9198926
Methods and compositions comprising rifabutin, clarithromycin, and clofazimine
granted -
US 9186411
Pharmaceutical composition
granted -
US 9072763
Methods and compositions for treating inflammatory bowel disease
granted -
CA 2919844
COMPOSES D'UREE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
granted -
CA 2908706
TRAITEMENTS UTILISANT L'ESLICARBAZEPINE ET L'ACETATE D'ESLICARBAZEPINE
granted -
US 8343511
Methods and compositions for treating inflammatory bowel disease
granted -
US 7977488
1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
granted -
US 6987175
Processes for preparing clarithromycin polymorphs
expired -
US 6812216
11-C-substituted derivatives of clarithromycin
expired -
US 6624292
Processes for preparing clarithromycin polymorphs
expired
Frequently asked questions
What is clarithromycin?
clarithromycin (CLARITHRO 250) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clarithromycin?
CLARITHRO 250 is a marketed brand name for clarithromycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clarithromycin?
clarithromycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.